MedPath

New Study Offers Hope for Type 2 Diabetes Patients Struggling with Weight Loss

The CT-388-104 Study is currently seeking participants with type 2 diabetes who have struggled to lose weight through diet and exercise. This study aims to test the safety and effectiveness of a new investigational drug targeting overweight or obesity in individuals with type 2 diabetes.

The CT-388-104 Study is a clinical trial focused on evaluating the safety and effectiveness of a selective GLP-1/GIP investigational drug for individuals living with overweight or obesity alongside type 2 diabetes. This study is particularly aimed at those who have previously attempted to lose weight through diet and exercise without success.
Eligibility Criteria:
  • Age between 18 and 75 years
  • Body Mass Index (BMI) of 25 or above
  • Diagnosis of type 2 diabetes
  • Previous unsuccessful attempts at weight loss through diet and exercise
Participants who qualify for the study may receive:
  • The investigational drug or placebo at no cost
  • Close medical care and follow-up throughout the study
  • Lifestyle management counseling
This study represents a significant opportunity for individuals with type 2 diabetes to explore new avenues for managing their condition and achieving weight loss goals. For more information on how to participate, interested individuals are encouraged to contact the study team directly.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Retatrutide Shows Promising Weight Loss Results Compared to Other GLP-1 Agonists

A recent study shows retatrutide, an investigational triple agonist, led to a 22.1% weight loss over 48 weeks, surpassing existing GLP-1 drugs.
Tirzepatide, commercially available as Zepbound, demonstrated a 17.8% weight loss over 72 weeks, highlighting its effectiveness in obesity management.

True You Weight Loss Launches Trials on Gastric Mucosal Ablation for Weight Management

True You Weight Loss initiates two clinical trials, MAINTAIN and REVAMP, to explore non-surgical weight loss solutions using gastric fundal mucosal ablation (GFMA).
The MAINTAIN trial assesses GFMA's effectiveness in preventing weight regain after discontinuing GLP-1 medications like semaglutide and tirzepatide.

Amgen's MariTide Shows Promise in Phase 2 Obesity Trial, Faces Market Competition

Amgen's MariTide demonstrated up to 20% average weight loss in obese or overweight individuals without diabetes over 52 weeks.
Patients with type 2 diabetes achieved up to 17% average weight loss and a 2.2% reduction in HbA1c levels with MariTide.

Tirzepatide Shows Sustained Weight Loss and Reduces Type 2 Diabetes Risk in Obese, Pre-diabetic Individuals

Tirzepatide demonstrated a 22.9% average weight loss over three years in obese or overweight individuals without type 2 diabetes.
The treatment significantly reduced the risk of type 2 diabetes progression by 94% compared to placebo over the 176-week study.

Response Pharmaceuticals Initiates Phase II Trial of RDX-002 for Weight Rebound After GLP-1 Agonist Discontinuation

Response Pharmaceuticals has begun enrolling participants in a Phase II trial of RDX-002 to manage weight rebound following the cessation of GLP-1 agonist treatment.
RDX-002, a gut-specific iMTP inhibitor, aims to reduce post-prandial triglyceride levels and improve cardiometabolic risk factors in patients.

UAB Launches Clinical Trial Evaluating Novel Therapy for Type 2 Diabetes

The University of Alabama at Birmingham (UAB) is conducting a clinical trial, TRANSCEND-T2D-2, to assess a new investigational medicine for type 2 diabetes.
The study aims to determine the efficacy of the investigational medicine in managing blood glucose levels and weight compared to existing treatments.

GLP-1 Receptor Agonists Show Promise for Weight Loss in Overweight and Obese Individuals Without Diabetes

A comprehensive study evaluating the benefit-harm balance of GLP-1 receptor agonists (RAs) for weight loss in individuals with overweight and obesity but without diabetes has found that these drugs can offer significant weight loss benefits, especially when aiming for a 10% reduction in body weight. However, the net benefit is highly dependent on individual treatment goals and tolerance for potential harms.

Emerging Role of GLP-1 Agonists in Obesity

GLP-1 agonists, initially developed for type 2 diabetes treatment, have shown significant efficacy in promoting weight loss in both preclinical and clinical studies. This review highlights the role of GLP-1 agonists in weight management, their pleiotropic effects, and their impact on hyperglycemia, insulin sensitivity, blood pressure, and cardio-metabolic and renal protection.

Real-world Weight Loss Effectiveness of GLP-1 Agonists in Type 2 Diabetes Patients

A study involving over 2,400 patients with type 2 diabetes and overweight or obesity found that initiating a GLP-1 agonist without a structured behavioral intervention led to a 2% weight loss at 72 weeks. One-third of the patients achieved clinically significant weight loss, defined as at least 5% change from baseline. The study highlights the potential of GLP-1 agonists for weight loss in real-world settings, despite the absence of structured weight loss interventions.

GLP-1 Receptor Agonists Show Significant Weight Loss Benefits in Overweight and Obese Patients

A comprehensive meta-analysis reveals that GLP-1 receptor agonists, particularly semaglutide and liraglutide, significantly contribute to weight loss in overweight or obese individuals, with or without type 2 diabetes mellitus (T2DM). The study highlights the efficacy of these medications in achieving ≥5% or ≥10% weight loss, with semaglutide SQ 2.4mg showing the highest effectiveness. Nausea was associated with greater weight loss, indicating its role as a clinical indicator of treatment efficacy.

Reference News

[1]
Do you have Type 2 Diabetes and have tried to Lose Weight? - The Reporter | UAB
uab.edu · Jan 8, 2025

CT-388-104 Study tests a GLP-1/GIP drug for overweight/obese individuals with type 2 diabetes. Eligibility: 18-75 years,...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy